Emicizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | Activated factor IX, factor X |
| Clinical data | |
| Routes of administration | Subcutaneous injection |
| ATC code | None |
| Legal status | |
| Legal status |
|
| Identifiers | |
| Synonyms | ACE910 |
| CAS Number | 1610943-06-0 |
| ChemSpider | none |
| UNII | 7NL2E3F6K3 |
Emicizumab (ACE910) is an investigational monoclonal antibody for the treatment of haemophilia A, being developed by Chugai.[1] A Phase I clinical trial found that it was well tolerated by healthy subjects.[2]
Mechanism of action
Emicizumab binds to both the activated coagulation factor IX and to factor X, mediating the activation of the latter. This is normally the function of coagulation factor VIII, which is missing in haemophilia A patients.[1][3]
References
- 1 2 H. Spreitzer (4 July 2016). "Neue Wirkstoffe - Emicizumab". Österreichische Apothekerzeitung (in German) (14/2016).
- ↑ Uchida, N; Sambe, T; Yoneyama, K; Fukazawa, N; Kawanishi, T; Kobayashi, S; Shima, M (2016). "A first-in-human phase 1 study of ACE910, a novel factor VIII–mimetic bispecific antibody, in healthy subjects". Blood. 127 (13): 1633–1641. doi:10.1182/blood-2015-06-650226. PMC 4817308
. PMID 26626991. - ↑ Shima, M; Hanabusa, H; Taki, M; Matsushita, T; Sato, T; Fukutake, K; Fukazawa, N; Yoneyama, K; Yoshida, H; Nogami, K (2016). "Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A". New England Journal of Medicine. 374 (21): 2044–53. doi:10.1056/NEJMoa1511769. PMID 27223146.
This article is issued from Wikipedia - version of the 11/23/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.